DARE BIOSCIENCE INC
DARE BIOSCIENCE INC
Aktie · US23666P1012 · DARE · A2DU45 (XNCM)
Übersicht Finanzkennzahlen
3,08 USD
-0,89 % -0,03 USD
NASDAQ CAPITAL MARKET (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
13.06.2025 19:53

Aktuelle Kurse von DARE BIOSCIENCE INC

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
DARE
USD
13.06.2025 19:53
3,08 USD
3,11 USD
-0,89 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % -2,31 % 6,84 % 6,65 % -3,08 % -42,92 % -74,32 %

Firmenprofil zu DARE BIOSCIENCE INC Aktie

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Unternehmensdaten

Name DARE BIOSCIENCE INC
Firma Daré Bioscience, Inc.
Symbol DARE
Website https://www.darebioscience.com
Heimatbörse XNCM NASDAQ CAPITAL MARKET
WKN A2DU45
ISIN US23666P1012
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Ms. Sabrina Martucci Johnson
Marktkapitalisierung 26 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,0 T
Adresse 3655 Nobel Drive, 92122 San Diego
IPO Datum 2014-04-10

Aktien-Splits

Datum Split
01.07.2024 1:12
20.07.2017 1:10

Kennungs-Wechsel

Datum Von Zu
22.07.2017 CERU DARE

Ticker Symbole

Name Symbol
NASDAQ DARE

Weitere Aktien

Investoren die DARE BIOSCIENCE INC die halten, haben auch folgende Aktien im Depot:
TABR.SUK SPC 18/25
TABR.SUK SPC 18/25 Anleihe
TREASURY CORPVICT. 2028
TREASURY CORPVICT. 2028 Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025